Budget Impact Test
NHS supremo hails Alexion and Roche deals, but defends budget controls
Andrew McConaghie
Alexion, BIA, Brexit, Budget Impact Test, MHRA, NHS England, Simon Stevens
0 Comment
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
Articles/ Pharma Market Access/ Rare diseases/ UK & Europe/ Views and analysis
Ultra-rare disease drugs: has access in England just got harder?
Andrew McConaghie
Budget Impact Test, market access, NHS England, NICE, Rare diseases
0 Comment
Gaining access to ultra-orphan drugs could become much more difficult.
Articles/ Brexit/ Healthcare/ Pharma Market Access/ Rare diseases/ UK & Europe/ Views and analysis
Pharma could take NHS England to court over new delaying tactics
Andrew McConaghie
Budget Impact Test, NHS, NHS England, UK market access
0 Comment
New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.
Pharma criticises ‘heavy handed’ NICE affordability test
Richard Staines
AbbVie, Budget Impact Test, cost-effectiveness, drug spend, Gilead, NHS, NICE
0 Comment
NHS England and NICE are attempting to reduce budget impact of drugs.
Articles/ Healthcare/ Pharma Market Access/ UK & Europe/ Views and analysis
The budget impact of new medicines
Leela Barham
Budget Impact Test, Drug funding, HTA, market access, NHS, NHSE, NICE, PPRS, Technology Appraisal
0 Comment
What could be the impact of proposed new ‘budget impact threshold’ for drugs?